KS Albain

776 total citations
18 papers, 607 citations indexed

About

KS Albain is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, KS Albain has authored 18 papers receiving a total of 607 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Cancer Research and 9 papers in Oncology. Recurrent topics in KS Albain's work include Advanced Breast Cancer Therapies (9 papers), Breast Cancer Treatment Studies (9 papers) and Cancer Treatment and Pharmacology (7 papers). KS Albain is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), Breast Cancer Treatment Studies (9 papers) and Cancer Treatment and Pharmacology (7 papers). KS Albain collaborates with scholars based in United States, Switzerland and Canada. KS Albain's co-authors include R. B. Livingston, Agnieszka Woźniak, Geoffrey R. Weiss, C. Harris Spiridonidis, Karen Kelly, John J. Crowley, S P Balcerzak, Lawrence Baker, David R. Gandara and EP Mamounas and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

KS Albain

18 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
KS Albain United States	8	488	427	111	107	39	18	607
B. E. Johnson United States	12	359 0.7×	388 0.9×	209 1.9×	101 0.9×	36 0.9×	17	534
Valorie F. Chan United States	7	653 1.3×	318 0.7×	140 1.3×	225 2.1×	32 0.8×	10	796
Natascha A. J. B. Peters Netherlands	8	392 0.8×	310 0.7×	64 0.6×	263 2.5×	23 0.6×	20	547
Eduardo J. Pennella United States	11	416 0.9×	377 0.9×	82 0.7×	62 0.6×	15 0.4×	33	578
Eric D. Mininberg United States	3	345 0.7×	307 0.7×	192 1.7×	96 0.9×	39 1.0×	6	494
Penelope Ann Bradbury Canada	9	227 0.5×	304 0.7×	87 0.8×	116 1.1×	29 0.7×	39	375
M.P. López-Cabrerizo Spain	7	404 0.8×	414 1.0×	144 1.3×	105 1.0×	72 1.8×	8	577
Graham Temple United Kingdom	12	441 0.9×	431 1.0×	288 2.6×	84 0.8×	82 2.1×	17	721
Yi-Sheng Huang China	11	471 1.0×	589 1.4×	140 1.3×	162 1.5×	36 0.9×	27	728
M. Lomas Spain	7	419 0.9×	364 0.9×	94 0.8×	52 0.5×	22 0.6×	23	518

Countries citing papers authored by KS Albain

Since Specialization

Citations

This map shows the geographic impact of KS Albain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by KS Albain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites KS Albain more than expected).

Fields of papers citing papers by KS Albain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by KS Albain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by KS Albain. The network helps show where KS Albain may publish in the future.

Co-authorship network of co-authors of KS Albain

This figure shows the co-authorship network connecting the top 25 collaborators of KS Albain. A scholar is included among the top collaborators of KS Albain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with KS Albain. KS Albain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Trivedi, Meghna S., Rebecca Shatsky, Rita Nanda, et al.. (2024). LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial. Annals of Oncology. 35. S1208–S1209. 1 indexed citations

Hortobagyi, G. N., Steven Shak, EP Winer, et al.. (2019). Abstract P3-11-02: Breast cancer-specific mortality (BCSM) in patients (pts) with node-negative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: A SEER-genomic population-based study. Cancer Research. 79(4_Supplement). P3–11. 9 indexed citations

Albain, KS, et al.. (2018). Abstract PD5-07: A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226. Cancer Research. 78(4_Supplement). PD5–7. 1 indexed citations

Fehrenbacher, L., CE Geyer, Priya Rastogi, et al.. (2018). Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). Cancer Research. 78(4_Supplement). GS1–2. 40 indexed citations

Ganz, PA, TB Julian, J. P. Costantino, et al.. (2016). Abstract S6-04: Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. Cancer Research. 76(4_Supplement). S6–4. 1 indexed citations

Tolaney, SM, DA Yardley, Beverly Moy, et al.. (2013). Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Cancer Research. 73(24_Supplement). S1–4. 22 indexed citations

Guo, Renhua, et al.. (2012). Abstract P1-12-04: Carboplatin, nab-paclitaxel and bevacizumab as first-line treatment for metastatic breast cancer.. Cancer Research. 72(24_Supplement). P1–12. 2 indexed citations

Gralow, JR, et al.. (2011). OT1-03-01: A Randomized Phase III Clinical Trial of Standard Adjuvant Endocrine Therapy +/− Chemotherapy in Patients (pts) with 1–3 Positive Nodes, Hormone Receptor (HR)-Positive and HER2−Negative Breast Cancer with Recurrence Score (RS) of 25 or Less: SWOG S1007.. Cancer Research. 71(24_Supplement). OT1–3. 7 indexed citations

Albain, KS, Andrei Zlobin, Prithi Rajan, et al.. (2011). S1-5: Modulation of Cancer and Stem Cell Biomarkers by the Notch Inhibitor MK-0752 Added to Endocrine Therapy for Early Stage ER+ Breast Cancer.. Cancer Research. 71(24_Supplement). S1–5. 17 indexed citations

10.

Albain, KS, et al.. (2011). S1-1: A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226.. Cancer Research. 71(24_Supplement). S1–1. 10 indexed citations

11.

Albain, KS. (2009). S40 Should genomic profiles be used to determine who should receive adjuvant chemotherapy?. The Breast. 18. S17–S17. 1 indexed citations

12.

Rychlik, Karen, et al.. (2009). Extended follow-up results from a prospective multi-center study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection, satisfaction, and anxiety.. Cancer Research. 69(2_Supplement). 3113–3113. 9 indexed citations

13.

Albain, KS. (2007). S30 Chemotherapy for endocrine responsive disease: An evolving story. The Breast. 16. S9–S9. 1 indexed citations

14.

Gordon, Michael A., Darcy Spicer, James H. Doroshow, et al.. (2006). Polymorphisms of DNA-repair genes associated with clinical outcome in metastatic breast cancer (MBC) patients treated with gemcitabine/cisplatin (GC) (California Cancer Consortium). Journal of Clinical Oncology. 24(18_suppl). 675–675. 2 indexed citations

15.

Salazar, Jaime de, Fikri İçlı, Tadeusz Pieńkowski, et al.. (2005). ABREAST: A new global registry of adjuvant strategies in patients with early stage breast cancer. Journal of Clinical Oncology. 23(16_suppl). 576–576. 11 indexed citations

16.

Lara, Primo N., Martin J. Edelman, James H. Doroshow, et al.. (2000). Salvage gemcitabine (GEM) in platinum-treated non-small cell lung cancer (NSCLC): A phase II California cancer consortium trial. Lung Cancer. 29(1). 58–58. 4 indexed citations

17.

Woźniak, Agnieszka, John J. Crowley, S P Balcerzak, et al.. (1998). Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.. Journal of Clinical Oncology. 16(7). 2459–2465. 462 indexed citations

18.

McKenzie, R. Scott, KS Albain, David Koch, et al.. (1991). A phase I trial of high-dose diaziquone and autologous bone marrow transplantation: an Illinois Cancer Council study.. Journal of Clinical Oncology. 9(8). 1487–1494. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact